<p>Summit Therapeutics（纳斯达克股票代码：SMMT - 获取免费报告）在周六发布给客户和投资者的研究报告中，被华尔街 Zen 的股票分析师从 “强烈卖出” 评级上调至 “卖出” 评级。</p>
<p>获取 <strong>Summit Therapeutics</strong> 的提醒：</p>
<ul>
<li>为什么华尔街支持这三只反弹股票</li>
</ul>
<p>其他几位股票研究分析师也对 SMMT 发布了报告。Stifel Nicolaus 在 4 月 8 日（星期三）的一份研究报告中开始覆盖 Summit Therapeutics 的股票。他们给予该股票 “买入” 评级，并设定目标价为 45.00 美元。Citizens Jmp 在 1 月 30 日（星期五）的一份研究报告中重新发布了 “市场表现优于大盘” 评级，并设定目标价为 40.00 美元。Jefferies Financial Group 在 3 月 16 日（星期一）的一份研究报告中将 Summit Therapeutics 的股票评级从 “买入” 下调至 “持有”，并将目标价从 42.00 美元下调至 15.00 美元。Citigroup 在 4 月 8 日（星期三）的一份研究报告中开始覆盖 Summit Therapeutics 的股票。他们对该股票设定了 “买入” 评级。最后，Piper Sandler 在周五的一份研究报告中将 Summit Therapeutics 的目标价从 17.00 美元下调至 16.00 美元，并对该股票设定了 “中性” 评级。两位股票研究分析师给予该股票 “强烈买入” 评级，八位给予 “买入” 评级，五位给予 “持有” 评级，二位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 28.17 美元。</p>
<p><strong>获取我们关于 Summit Therapeutics 的最新研究报告</strong></p>
<h2>Summit Therapeutics 股票表现</h2>
<ul>
<li>MarketBeat 周报 – 11/4 - 11/8</li>
</ul>
<p>纳斯达克：SMMT 周五开盘价为 16.11 美元。Summit Therapeutics 的年低为 13.83 美元，年高为 30.98 美元。该公司的市值为 125 亿美元，市盈率为-11.11，贝塔值为-1.25。该公司的 50 日移动平均线为 18.43 美元，200 日移动平均线为 17.87 美元。</p>
<p>Summit Therapeutics（纳斯达克：SMMT - 获取免费报告）最后一次发布财报是在 4 月 30 日（星期四）。该公司报告的每股收益（EPS）为（0.24）美元，超出市场共识预期的（0.27）美元，超出幅度为 0.03 美元。作为一个整体，股票研究分析师预测 Summit Therapeutics 在当前财政年度的每股收益将为-1.31 美元。</p>
<h2>机构资金流入和流出</h2>
<ul>
<li>Summit Therapeutics：他们的肺癌药物是游戏规则改变者吗？</li>
</ul>
<p>对冲基金和其他机构投资者最近买入和卖出了该股票的股份。Crowley Wealth Management Inc.在第三季度将其在 Summit Therapeutics 的股份增加了 66.7%。Crowley Wealth Management Inc.现在拥有该公司 1,500 股股票，价值 31,000 美元，此前在上个季度又购买了 600 股。Ball &amp; Co Wealth Management Inc.在第一季度购买了 Summit Therapeutics 的新头寸，价值约 28,000 美元。Kestra Advisory Services LLC 在第四季度购买了 Summit Therapeutics 的新头寸，价值约 28,000 美元。Parallel Advisors LLC 在第三季度购买了 Summit Therapeutics 的新头寸，价值约 39,000 美元。最后，T. Rowe Price Investment Management Inc.在第四季度将其在 Summit Therapeutics 的股份增加了 2,654.4%。T. Rowe Price Investment Management Inc.现在拥有该公司 1,873 股股票，价值 33,000 美元，此前在上个季度又购买了 1,805 股。4.61% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Summit Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Summit Therapeutics plc 是一家临床阶段的生物技术公司，致力于发现和开发针对严重和危及生命疾病的精准药物。该公司采用针对性的药物设计方法，专注于与现有疗法不同的新机制。</p>
<p>Summit 的主要资产，ridinilazole（前称 SMT19969），正在开发用于治疗艰难梭状芽孢杆菌感染，并已获得美国的快速通道和合格感染性疾病产品的认证。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Summit Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01NVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01NVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Summit Therapeutics 吗？</h2>
<p>在你考虑 Summit Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Summit Therapeutics 并不在名单上。</p>
<p>虽然 Summit Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看这五只股票</p>

Summit治疗

<p>华尔街禅将 Summit Therapeutics（NASDAQ:SMMT）的评级从 “强烈卖出” 上调至 “卖出”。其他分析师的意见各不相同，Stifel Nicolaus 给予 “买入” 评级，目标价为 45 美元，而 Jefferies 则将其评级下调至 “持有”，目标价为 15 美元。目前，该股票的共识评级为 “适度买入”，目标价为 28.17 美元。Summit Therapeutics 报告的季度每股收益为（0.24 美元），超出预期。该公司专注于针对严重疾病的精准医疗，其主要资产针对艰难梭状芽胞杆菌感染</p>

<p>Summit Therapeutics (NASDAQ:SMMT - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a &#34;strong sell&#34; rating to a &#34;sell&#34; rating in a research report issued to clients and investors on Saturday.</p>
<div class="lb-trans"><p>Summit Therapeutics（纳斯达克股票代码：SMMT - 获取免费报告）在周六发布给客户和投资者的研究报告中，被华尔街 Zen 的股票分析师从 “强烈卖出” 评级上调至 “卖出” 评级。</p>
</div><p>Get <strong>Summit Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Summit Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Why Wall Street Is Backing These 3 Comeback Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么华尔街支持这三只反弹股票</li>
</ul>
</div><p>Several other equities research analysts have also issued reports on SMMT. Stifel Nicolaus began coverage on shares of Summit Therapeutics in a research note on Wednesday, April 8th. They set a &#34;buy&#34; rating and a $45.00 target price on the stock. Citizens Jmp reissued a &#34;market outperform&#34; rating and set a $40.00 target price on shares of Summit Therapeutics in a research note on Friday, January 30th. Jefferies Financial Group lowered shares of Summit Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating and lowered their target price for the stock from $42.00 to $15.00 in a research note on Monday, March 16th. Citigroup began coverage on shares of Summit Therapeutics in a research note on Wednesday, April 8th. They set a &#34;buy&#34; rating on the stock. Finally, Piper Sandler lowered their target price on shares of Summit Therapeutics from $17.00 to $16.00 and set a &#34;neutral&#34; rating on the stock in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $28.17.</p>
<div class="lb-trans"><p>其他几位股票研究分析师也对 SMMT 发布了报告。Stifel Nicolaus 在 4 月 8 日（星期三）的一份研究报告中开始覆盖 Summit Therapeutics 的股票。他们给予该股票 “买入” 评级，并设定目标价为 45.00 美元。Citizens Jmp 在 1 月 30 日（星期五）的一份研究报告中重新发布了 “市场表现优于大盘” 评级，并设定目标价为 40.00 美元。Jefferies Financial Group 在 3 月 16 日（星期一）的一份研究报告中将 Summit Therapeutics 的股票评级从 “买入” 下调至 “持有”，并将目标价从 42.00 美元下调至 15.00 美元。Citigroup 在 4 月 8 日（星期三）的一份研究报告中开始覆盖 Summit Therapeutics 的股票。他们对该股票设定了 “买入” 评级。最后，Piper Sandler 在周五的一份研究报告中将 Summit Therapeutics 的目标价从 17.00 美元下调至 16.00 美元，并对该股票设定了 “中性” 评级。两位股票研究分析师给予该股票 “强烈买入” 评级，八位给予 “买入” 评级，五位给予 “持有” 评级，二位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 28.17 美元。</p>
</div><p><strong>Get Our Latest Research Report on Summit Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Summit Therapeutics 的最新研究报告</strong></p>
</div><h2>Summit Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Summit Therapeutics 股票表现</h2>
</div><ul>
<li>MarketBeat Week in Review – 11/4 - 11/8</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 11/4 - 11/8</li>
</ul>
</div><p>NASDAQ:SMMT opened at $16.11 on Friday. Summit Therapeutics has a one year low of $13.83 and a one year high of $30.98. The firm has a market cap of $12.50 billion, a price-to-earnings ratio of -11.11 and a beta of -1.25. The firm's fifty day moving average is $18.43 and its two-hundred day moving average is $17.87.</p>
<div class="lb-trans"><p>纳斯达克：SMMT 周五开盘价为 16.11 美元。Summit Therapeutics 的年低为 13.83 美元，年高为 30.98 美元。该公司的市值为 125 亿美元，市盈率为-11.11，贝塔值为-1.25。该公司的 50 日移动平均线为 18.43 美元，200 日移动平均线为 17.87 美元。</p>
</div><p>Summit Therapeutics (NASDAQ:SMMT - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.03. As a group, equities research analysts predict that Summit Therapeutics will post -1.31 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Summit Therapeutics（纳斯达克：SMMT - 获取免费报告）最后一次发布财报是在 4 月 30 日（星期四）。该公司报告的每股收益（EPS）为（0.24）美元，超出市场共识预期的（0.27）美元，超出幅度为 0.03 美元。作为一个整体，股票研究分析师预测 Summit Therapeutics 在当前财政年度的每股收益将为-1.31 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><ul>
<li>Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?</li>
</ul>
<div class="lb-trans"><ul>
<li>Summit Therapeutics：他们的肺癌药物是游戏规则改变者吗？</li>
</ul>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the stock. Crowley Wealth Management Inc. lifted its stake in Summit Therapeutics by 66.7% in the 3rd quarter. Crowley Wealth Management Inc. now owns 1,500 shares of the company's stock valued at $31,000 after buying an additional 600 shares in the last quarter. Ball &amp; Co Wealth Management Inc. purchased a new position in Summit Therapeutics in the 1st quarter valued at about $28,000. Kestra Advisory Services LLC purchased a new position in Summit Therapeutics in the 4th quarter valued at about $28,000. Parallel Advisors LLC purchased a new position in Summit Therapeutics in the 3rd quarter valued at about $39,000. Finally, T. Rowe Price Investment Management Inc. lifted its stake in Summit Therapeutics by 2,654.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,873 shares of the company's stock valued at $33,000 after buying an additional 1,805 shares in the last quarter. 4.61% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近买入和卖出了该股票的股份。Crowley Wealth Management Inc.在第三季度将其在 Summit Therapeutics 的股份增加了 66.7%。Crowley Wealth Management Inc.现在拥有该公司 1,500 股股票，价值 31,000 美元，此前在上个季度又购买了 600 股。Ball &amp; Co Wealth Management Inc.在第一季度购买了 Summit Therapeutics 的新头寸，价值约 28,000 美元。Kestra Advisory Services LLC 在第四季度购买了 Summit Therapeutics 的新头寸，价值约 28,000 美元。Parallel Advisors LLC 在第三季度购买了 Summit Therapeutics 的新头寸，价值约 39,000 美元。最后，T. Rowe Price Investment Management Inc.在第四季度将其在 Summit Therapeutics 的股份增加了 2,654.4%。T. Rowe Price Investment Management Inc.现在拥有该公司 1,873 股股票，价值 33,000 美元，此前在上个季度又购买了 1,805 股。4.61% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Summit Therapeutics</h2>
<div class="lb-trans"><h2>关于 Summit Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.</p>
<div class="lb-trans"><p>Summit Therapeutics plc 是一家临床阶段的生物技术公司，致力于发现和开发针对严重和危及生命疾病的精准药物。该公司采用针对性的药物设计方法，专注于与现有疗法不同的新机制。</p>
</div><p>Summit's lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.</p>
<div class="lb-trans"><p>Summit 的主要资产，ridinilazole（前称 SMT19969），正在开发用于治疗艰难梭状芽孢杆菌感染，并已获得美国的快速通道和合格感染性疾病产品的认证。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Summit Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Summit Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01NVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=SMMT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Summit Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Summit Therapeutics 吗？</h2>
</div><p>Before you consider Summit Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Summit Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Summit Therapeutics 并不在名单上。</p>
</div><p>While Summit Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Summit Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Summit Therapeutics (NASDAQ:SMMT) Raised to "Sell" at Wall Street Zen

Market Beat

Summit 治疗公司（纳斯达克股票代码：SMMT）在华尔街 Zen 被上调至 “卖出” 评级